2Aus G,Abbou CC,Heidenreich A,et al.Treatment:secondline treatment of CAP after hormonal therapy.EAU guidelines on prostate cancer,2003,67～77. 被引量：1
3Bubley GJ,Cardccci M,Dahut W,et al.Eligibility and response guidelines for phase Ⅱ clinical trails in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group.J Clin Oncol,1999,17:3461～3467. 被引量：1
4Joyce R,Fenton MA,Rode P,et al.High dose Bicalutamide for androgen independent prostate cancer:Effect of prior hormonal therapy.J Urol,1998,159(1):149～153. 被引量：1
7Scholz M,Jennirich R,Strum S,et al.Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.J Urol,2005.173:1947～1952. 被引量：1
8Wikinson S,Chodak G.An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.Eur Urol,2004,45:581～585. 被引量：1
9Nakabavashi M,Xie W,Reqan MM,et al.Response to lowdose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.Cancer,2006,107:975～981. 被引量：1
10Petrylak DP,Tangen CH,Hussain MHA,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced prostate cancer.N Engl J Med,2004,351:1513～1520. 被引量：1
2OH WK,Kantoff PW.Management of hormone refractory prostate cancer:current standards and future prospects[J].J Urol,1998,160(4):1220-1229. 被引量：1
3Scher HI,Liebertz C,Kelly WK,et al.Bicalutamide for advanced prostate cancer:the nature versus treated history of disease[J].J Clin Oncol,1997,15(8):2928-2938. 被引量：1
4Joyce R,Fenton MA,Rode P,et al.High dose bicalutamide for androgen independent prostate cancer:effect of prior hormonal therapy[J].J Urol,1997,159(1):149-153. 被引量：1
5Kucuk O,Fisher E,Moinpour CM,et al.Phase Ⅱtrial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed:a Southwest Oncology Group study(SWOG 9235)[J].Urol,2001,58(1):53-58. 被引量：1
6Grawford ED,Eisenberge MA, Mcleod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med, 1989,321:419 - 423. 被引量：1
7Small EJ,Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawl. J Urol, 1997,4: 1204 - 1207. 被引量：1
8Osborn JL. Smith DC,Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncolo , 1997,20:308-310. 被引量：1
9OH WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 1998, 160:1220- 1229. 被引量：1
10Joyce R,Fenton MA,Rode P, et al. Hight dose bicalutanide for androgen independent prostate cancer: Effect of prior hormonal theraPy. J Urol, 1998,159:149 - 153. 被引量：1
